USP7 and breast carcinoma: Invasive breast cancer showed the highest level of amplification and gains of the USP7/C16orf72/HAPSTR1 locus in up to 55% of tumors (p < 0.001; Fig. 6A), suggesting that these two co-amplified negative p53 regulators might cooperate in modulating p53 levels in cancer.